Tevogen Bio Holdings Reports Reduced Q2 2025 Net Loss of $5.5M, Down from $9.7M in Q2 2024, as Operating Efficiency Improves
Reuters
Aug 20
<a href="https://laohu8.com/S/TVGN">Tevogen Bio Holdings</a> Reports Reduced <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Net Loss of $5.5M, Down from $9.7M in Q2 2024, as Operating Efficiency Improves
Tevogen Bio Holdings Inc. reported a reduction in its operational losses for the second quarter of 2025. The company announced a loss from operations of $5.4 million for the quarter ended June 30, 2025, a notable improvement compared to the $8.6 million loss reported for the same period in 2024. The net loss for the quarter was $5.5 million, down from $9.7 million in the second quarter of 2024. Tevogen continues to focus on maximizing capital efficiency and has maintained access to financing to support its growth strategies. The company is advancing its infrastructure, artificial intelligence capabilities, and internal strengths in a market experiencing limited growth. It also anticipates generating revenue by the end of 2026 and is actively exploring options to address its limited tradable float to better meet investor demand. In a strategic move, Tevogen is in the process of establishing its own GMP manufacturing facility, which aims to enhance control over its production processes and accelerate product development timelines. Detailed financial results are available in the company's Form 10-Q filed with the SEC.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9514884-en) on August 19, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.